#ESMO25: Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelmnews2025-10-20T14:37:56+00:00October 20th, 2025|Endpoints News|
FDA approves Roche’s CD20 antibody Gazyva for lupus nephritisnews2025-10-20T05:00:46+00:00October 20th, 2025|Endpoints News|
#ESMO25: Datroway, Trodelvy contest in triple negative breast cancer heats upnews2025-10-19T08:14:23+00:00October 19th, 2025|Endpoints News|
#ESMO25: Padcev-Keytruda combo extends survival in Phase 3 bladder cancer trialnews2025-10-18T14:30:51+00:00October 18th, 2025|Endpoints News|
#ESMO25: Enhertu could move into ‘curative’ breast cancer setting on the strength of Phase 3 datanews2025-10-18T14:30:08+00:00October 18th, 2025|Endpoints News|
Meet the first nine recipients of the FDA’s new vouchernews2025-10-17T19:31:44+00:00October 17th, 2025|Endpoints News|
CHMP rejects Sanofi’s Rezurock over clinical data issues, but recommends Wayrilznews2025-10-17T14:44:13+00:00October 17th, 2025|Endpoints News|
Trump announces ‘most favored nation’ deal with EMD Serono to boost IVF accessnews2025-10-16T21:42:18+00:00October 16th, 2025|Endpoints News|
Pfizer CEO says US must compete better against China, not block itnews2025-10-16T19:06:09+00:00October 16th, 2025|Endpoints News|
California to offer its own, cheaper version of insulin pensnews2025-10-16T17:05:45+00:00October 16th, 2025|Endpoints News|
